BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38578473)

  • 1. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
    Benetti-Pinto CL; Prestes Nácul A; Rosa-E-Silva ACJS; Maciel GAR; Dos Santos Nunes Nogueira V; Condé Lamparelli Elias P; Martins M; Kasuki L; Mendes Garmes H; Glezer A
    Arch Endocrinol Metab; 2024 Apr; 68():e230504. PubMed ID: 38578473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
    Glezer A; Mendes Garmes H; Kasuki L; Martins M; Condé Lamparelli Elias P; Dos Santos Nunes Nogueira V; Rosa-E-Silva ACJS; Maciel GAR; Benetti-Pinto CL; Prestes Nácul A
    Arch Endocrinol Metab; 2024 Apr; 68():e230502. PubMed ID: 38578472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
    Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
    Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
    Pekić S; Medic Stojanoska M; Popovic V
    Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of prolactinomas in Brazil: an electronic survey.
    Vilar L; Naves LA; Casulari LA; Azevedo MF; Albuquerque JL; Serfaty FM; Pinho Barbosa FR; de Oliveira AR; Montenegro RM; Montenegro RM; Ramos AJ; Dos Santos Faria M; Musolino NR; Gadelha MR; Boguszewski CL; Bronstein MD
    Pituitary; 2010 Sep; 13(3):199-206. PubMed ID: 20107911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperprolactinemia in the postmenopause: versions and contraversions].
    Leshchenko OY
    Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin and reproductive medicine.
    Davis JR
    Curr Opin Obstet Gynecol; 2004 Aug; 16(4):331-7. PubMed ID: 15232488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to the Patient With Prolactinoma.
    Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
    Pereira AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinemia after menopause: Diagnosis and management.
    Auriemma RS; Pirchio R; Pivonello R; Colao A
    Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of prolactinomas during pregnancy.
    Witek P; Zieliński G
    Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactinomas.
    Glezer A; Bronstein MD
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hyperprolactinemia in post-menopausal women: pros.
    Iacovazzo D; De Marinis L
    Endocrine; 2015 Feb; 48(1):76-8. PubMed ID: 25112228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprolactinemia and infertility.
    Shibli-Rahhal A; Schlechte J
    Endocrinol Metab Clin North Am; 2011 Dec; 40(4):837-46. PubMed ID: 22108283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.